Position in VIVS
as of Jun 30, 2026
· filed Jul 8, 2026
Position Value
$214
New position
Shares Held
200
first reported quarter
Ownership
0.001%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#9
of 25 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026FNY Investment Advisers, LLC holds $6,470,178 across 59 Biotechnology names. VIVS ranks #50 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABVX |
Abivax S.A.
|
7,605 | $1,013,442 | |
| 2 | SGMT |
Sagimet Biosciences Inc.
|
109,250 | $844,502 | |
| 3 | 5,000 | $663,650 | |||
| 4 | JANX |
Janux Therapeutics, Inc.
|
30,850 | $473,856 | |
| 5 | NKTR |
Nektar Therapeutics
|
5,500 | $383,955 | |
| 6 | VERU |
Veru Inc.
|
105,081 | $328,903 | |
| 7 | VKTX |
Viking Therapeutics, Inc.
|
8,170 | $318,711 | |
| 8 | XENE |
Xenon Pharmaceuticals Inc.
|
4,000 | $241,440 |
All Filings in VIVS
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $214 | 200 | Shares | Sole | 2026-07-08 | |
| No filing history on record for this holder in this stock. | ||||||